FIELD: infectology.
SUBSTANCE: used to predict the outcome of the infectious process within 12 months after a new coronavirus infection. A study of biochemical blood parameters is carried out together with clinical parameters. The content of TNF-alpha, nitrites, MDA, the activity of trypsin-like proteinases, and the activity of elastase-like proteinases are determined in the blood serum. Discriminant functions Y1 and Y2 are calculated using the equations:
Y1 = -249.778+0.049x1+4.650x2+5.145x3+0.202x4-0.022x5-34.823x6+19.838x7+5.990x8-16.499x9+24.184x10 – unfavorable outcome,
Y2=-112.293+0.007x1+3.241x2+3.518x3+0.133x4-0.016x5-22.405x6+17.880x7+3.379x8-6.450x9+14.531x10 – favorable outcome, where
Y is the linear discriminant function;
x1 is the TNF-alpha content, pg/ml;
x2 is the nitrite content, µmol/l;
x3 is the MDA content, µmol/ml;
x4 is the activity of trypsin-like proteinases, nmol BANE/min⋅ml;
x5 is the activity of elastase-like proteinases, nmol BANE/min⋅ml;
x6 is the presence of malignant neoplasms: 1 is the absence of malignant neoplasm; 2 is the presence of malignant neoplasms;
x7 is the presence of hypertension; 1 is the absence of hypertension; 2 is the presence of hypertension;
x8 is the presence of type 2 diabetes mellitus: 1 is the absence of type 2 diabetes mellitus; 2 is the presence of type 2 diabetes mellitus;
x9 is the presence of gastrointestinal diseases: 1 is the absence of gastrointestinal diseases, 2 is the presence of gastrointestinal diseases;
x10 is the presence of respiratory failure during the period of infection with a new coronavirus infection: 1 is the absence of respiratory failure, 2 is the presence of respiratory failure. If Y1>Y2, an unfavorable outcome of the infectious process is predicted after suffering a new coronavirus infection for 12 months. If Y1<Y2, then the favorable outcome.
EFFECT: increasing the information content of predicting the outcome of the infectious process within 12 months after suffering a new coronavirus infection by studying biochemical blood parameters together with clinical parameters and conducting analysis using a mathematical apparatus.
1 cl, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETECTING MICROCIRCULATORY DISORDERS AS A BIOMARKER OF INTERSTITIAL CHANGES IN THE LUNGS OF PATIENTS UNDERGONE A NEW CORONAVIRUS INFECTION | 2022 |
|
RU2790513C1 |
METHOD FOR PREDICTING COURSE OF PNEUMONIA WITH ALVEOLAR TYPE OF LUNG TISSUE INFILTRATION | 2020 |
|
RU2753745C1 |
METHOD FOR PREDICTION OF RISK OF DEVELOPING INFLAMMATORY GASTROINTESTINAL DISEASES IN PATIENTS AFTER SUFFERING SARS-CoV2 ASSOCIATED PNEUMONIA | 2023 |
|
RU2816013C1 |
METHOD FOR EVALUATING EFFECTIVENESS OF TREATMENT OF PNEUMONIA | 2020 |
|
RU2753744C1 |
METHOD FOR PREDICTING THE RISK OF DEATH WITHIN 6 MONTHS AFTER SUFFERING A NEW CORONAVIRUS INFECTION COVID-19 | 2021 |
|
RU2766302C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF PULMONARY TISSUE INFILTRATION TYPE IN PNEUMONIA | 2020 |
|
RU2738450C1 |
DIAGNOSTIC METHOD OF COMATOSE STATE IN CASE OF PNEUMONIA | 2020 |
|
RU2738442C1 |
METHOD FOR EVALUATING EFFECTIVENESS OF TREATMENT OF PNEUMONIA | 2020 |
|
RU2753746C1 |
METHOD FOR PREDICTION OF LETHAL OUTCOME IN PATIENTS WITH CYTOKINE STORM ASSOCIATED WITH COVID-19 | 2022 |
|
RU2825710C2 |
METHOD FOR PREDICTING ONSET OF DEATH IN COVID-19 PATIENTS AGED 60 YEARS AND OLDER | 2023 |
|
RU2805263C1 |
Authors
Dates
2023-11-14—Published
2023-07-28—Filed